Product Information
Registration Status: ActiveTAZIME FOR INJECTION 1g/VIAL is approved to be sold in Singapore with effective from 2002-11-10. It is marketed by SHOEI UNIVERSAL CORPORATION PTE LTD, with the registration number of SIN12096P.
This product contains Ceftazidime 1g/vial in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS, INTRAMUSCULAR use.
This product is manufactured by HANMI PHARM CO LTD in KOREA, and in REPUBLIC OF.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
Indication
For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
Mechanism of Action
The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
Pharmacokinetics
- Absorption
- The absorption of ceftazidime is directly proportional to the size of the dose.
- Distribution
- Metabolism
- Elimination
Clearance
* 115 mL/min
Toxicity
Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
Active Ingredient/Synonyms
CAZ | Ceftazidim | Ceftazidima | Ceftazidime | Ceftazidime anhydrous | Ceftazidimum | Ceftazidime |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.